Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product, Procedure and Disease Indication: Global Opportunity Analysis and Industry Forecast, 2021-2028

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

2.1. Key findings of the study
2.2. CXO perspective

3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2019
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Surge in obese population
3.5.1.2. Technological advancements
3.5.1.3. Rise in prevalence rate of diseases that require endoscopy devices
3.5.1.4. Growth in patient preference for minimally invasive surgeries
3.5.1.5. Favorable FDA approvals
3.5.1.6. Shorter recovery time and minimal postoperative complications
3.5.2. Restraints
3.5.2.1. Dearth of trained physicians and endoscopists
3.5.2.2. Infections caused by few endoscopes
3.5.3. Opportunities
3.5.3.1. Unmet medical demands in developing countries
3.5.3.2. Lucrative opportunities in emerging economies
3.6. COVID-19 impact analysis
3.7. Clinical data analysis
3.7.1. Intragastric balloons
3.7.2. AspireAssist
3.7.3. Revita DMR System
3.7.4. EndoBarrier
3.7.5. Incision-less Anastomosis System (IAS)
3.7.6. OverStitch Endoscopic Suturing System
3.7.7. Endomina
3.7.8. Plication Device
3.7.9. Endostitch

4.1. Overview
4.1.1. Market size and forecast
4.2. Endoscopes
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Mechanical endoscopic equipment
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Visualization and documentation systems
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Accessories
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Other endoscopy equipment
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country

5.1. Overview
5.1.1. Market size and forecast
5.2. Gastric balloons
5.2.1. Key market trends and opportunities
5.2.2. Market size and forecast
5.2.3. Market analysis, by country
5.3. Aspiration therapy
5.3.1. Key trends and opportunities
5.3.2. Market size and forecast
5.3.3. Market analysis, by country
5.4. Endoscopic sleeve gastroplasty
5.4.1. Key market trends and opportunities
5.4.2. Market size and forecast
5.4.3. Market analysis, by country
5.5. Gastric injections
5.5.1. Key market trends and opportunities
5.5.2. Market size and forecast
5.5.3. Market analysis, by country
5.6. Lap band surgery
5.6.1. Key market trends and opportunities
5.6.2. Market size and forecast
5.6.3. Market analysis, by country
5.7. Others
5.7.1. Key market trends and opportunities
5.7.2. Market size and forecast
5.7.3. Market analysis, by country

6.1. Overview
6.1.1. Market size and forecast
6.2. Obesity
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis, by country
6.3. Type II Diabetes
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis, by country
6.4. Nonalcoholic Steatohepatitis (NASH)
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis, by country

7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by product type
7.2.4. Market size and forecast, by procedure
7.2.5. Market size and forecast, by disease indication
7.2.5.1. U.S.
7.2.5.1.1. U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.1.2. U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.1.3. U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.2.5.2. Canada
7.2.5.2.1. Canada Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.2.2. Canada Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.2.3. Canada Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.2.5.3. Mexico
7.2.5.3.1. Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.3.2. Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.3.3. Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.1.2. Germany Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.1.3. Germany Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.2. France
7.3.2.2.1. France Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.2.2. France Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.2.3. France Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.3. U. K.
7.3.2.3.1. U. K. Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.3.2. U. K. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.3.3. U. K. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.4. Italy
7.3.2.4.1. Italy Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.4.2. Italy Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.4.3. Italy Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.5. Spain
7.3.2.5.1. Spain Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.5.2. Spain Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.5.3. Spain Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.6.2. Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.6.3. Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.3. Market size and forecast, by product type
7.4.4. Market size and forecast, by procedure
7.4.5. Market size and forecast, by disease indication
7.4.5.1. China
7.4.5.1.1. China Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.1.2. China endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.1.3. China endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.2. Japan
7.4.5.2.1. Japan Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.2.2. Japan endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.2.3. Japan endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.3. India
7.4.5.3.1. India Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.3.2. India endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.3.3. India endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.4. Australia
7.4.5.4.1. Australia Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.4.2. Australia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.4.3. Australia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.5. Rest of Asia-Pacific
7.4.5.5.1. Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.5.2. Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.5.3. Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.3. Market size and forecast, by product type
7.5.4. Market size and forecast, by procedure
7.5.5. Market size and forecast, by disease indication
7.5.5.1. Brazil
7.5.5.1.1. Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.1.2. Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.1.3. Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.2. Saudi Arabia
7.5.5.2.1. Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.2.2. Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.2.3. Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.3. South Africa
7.5.5.3.1. South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.3.2. South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.3.3. South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.4.2. Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.4.3. Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

8.1. APOLLO ENDOSURGERY INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. ASPIRE BARIATRICS INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segment
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments
8.3. ENDO TOOLS THERAPEUTICS S. A.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segment
8.3.4. Product portfolio
8.4. FRACTYL LABORATORIES INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. GI DYNAMICS INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segment
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. GI WINDOWS INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segment
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments
8.7. MEDTRONIC PLC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. OBALON THERAPEUTICS INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segment
8.8.4. Product portfolio
8.8.5. Business Performance
8.9. RESHAPE LIFESCIENCES INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product portfolio
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. SPATZ FGIA INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segment
8.10.4. Product portfolio
8.11. USGI MEDICAL INC.
8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Product portfolio
8.11.5. Key strategic moves and developments

TABLE 01. OVERVIEW OF FDA STATUS FOR DEVICES USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 02. CLINICAL DATA OF THE GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 03. CLINICAL DATA OF THE OTHER GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 04. CLINICAL PIPELINE ANALYSIS OF GASTRIC BALLOONS
TABLE 05. CLINICAL DATA OF THE ASPIRATION THERAPY DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 06. CLINICAL PIPELINE ANALYSIS OF ASPIRATION THERAPY DEVICE
TABLE 07. CLINICAL DATA OF THE REVITA DMR SYSTEM USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 08. CLINICAL PIPELINE ANALYSIS OF REVITA DMR SYSTEM
TABLE 09. CLINICAL DATA OF ENDOBARRIER USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 10. CLINICAL PIPELINE ANALYSIS OF ENDOBARRIER
TABLE 11. CLINICAL DATA OF INCISION-LESS ANASTOMOSIS SYSTEM (IAS) USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 12. CLINICAL PIPELINE ANALYSIS OF INCISIONLESS ANASTOMOSIS
TABLE 13. CLINICAL DATA OF OVERSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 14. CLINICAL PIPELINE ANALYSIS OF OVERSTITCH ENDOSCOPIC SUTURING SYSTEM
TABLE 15. CLINICAL DATA OF ENDOMINA USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 16. CLINICAL PIPELINE ANALYSIS OF ENDOMINA
TABLE 17. CLINICAL DATA OF PLICATION DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 18. CLINICAL PIPELINE ANALYSIS OF PLICATION DEVICE
TABLE 19. CLINICAL DATA OF ENDOSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 20. CLINICAL PIPELINE ANALYSIS OF ENDOSTITCH
TABLE 21. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019–2028 ($MILLION)
TABLE 22. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY REGION, 2019–2028 ($MILLION)
TABLE 23. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY REGION, 2019–2028 ($MILLION)
TABLE 24. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEM, BY REGION, 2019–2028 ($MILLION)
TABLE 25. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY REGION, 2019–2028 ($MILLION)
TABLE 26. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY REGION, 2019–2028 ($MILLION)
TABLE 27. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019–2028 ($MILLION)
TABLE 28. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY REGION, 2019–2028 ($MILLION)
TABLE 29. ENDOSOCOPY DEVICES MARKET FOR ASPIRATION THEREAPY, BY REGION, 2019–2028 ($MILLION)
TABLE 30. ENDOSCOPIC DEVICES MARKET FOE ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2019–2028 ($MILLION)
TABLE 31. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTION, BY REGION, 2019–2028 ($MILLION)
TABLE 32. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET LAP BAND SURGERY, BY REGION, 2019–2028 ($MILLION)
TABLE 33. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET OTHERS, BY REGION, 2019–2028 ($MILLION)
TABLE 34. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION 2019-2028($MILLION)
TABLE 35. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY REGION, 2019-2028 ($MILLION)
TABLE 36. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY REGION, 2019-2028 ($MILLION)
TABLE 37. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY REGION, 2019-2028 ($MILLION)
TABLE 38. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION, 2019-2028 ($MILLION)
TABLE 39. NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 40. NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 41. NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 42. NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 43. U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028
TABLE 44. U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 45. U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 46. CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 47. CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 48. CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 49. MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 50. MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 51. MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 52. EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 53. GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 54. GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 55. GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 56. FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 57. FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 58. FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 59. U. K. ENDOSCOPY DEVICES MARKET FOR OBESITY, TYPE II DIABETES, AN BGT5D NASH, BY PRODUCT, 2019-2028
TABLE 60. U. K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 61. U. K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 62. ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 63. ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 64. ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 65. SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 66. SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 67. ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 68. REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 69. REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 70. REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 71. ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 72. ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 73. ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 74. ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 75. CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 76. CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 77. CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 78. JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 79. JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 80. JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 81. INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 82. INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 83. INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 84. AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 85. AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 86. AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 87. REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 88. REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 89. REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 90. LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 91. LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 92. LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 93. LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 94. BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 95. BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 96. BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 97. SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 98. SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 99. SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 100. SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 101. SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 102. SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 103. REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 104. REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 105. REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 106. APOLLO ENDOSURGERY: COMPANY SNAPSHOT
TABLE 107. APOLLO ENDOSURGERY: OPERATING SEGMENT
TABLE 108. APOLLO ENDOSURGERY: PRODUCT PORTFOLIO
TABLE 109. ASPIRE BARIATRICS: COMPANY SNAPSHOT
TABLE 110. ASPIRE BARIATRICS: OPERATING SEGMENT
TABLE 111. ASPIRE BARIATRICS: PRODUCT PORTFOLIO
TABLE 112. ASPIRE BARIATRICS: PRODUCT PORTFOLIO
TABLE 113. ENDO TOOLS THERAPEUTICS: COMPANY SNAPSHOT
TABLE 114. ENDO TOOLS THERAPEUTICS: OPERATING SEGMENT
TABLE 115. ENDO TOOLS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 116. FRACTYL LABORATORIES: COMPANY SNAPSHOT
TABLE 117. FRACTYL LABORATORIES: OPERATING SEGMENTS
TABLE 118. FRACTYL LABORATORIES: PRODUCT PORTFOLIO
TABLE 119. FRACTYL LABORATORIES: PRODUCT PORTFOLIO
TABLE 120. GI DYNAMICS: COMPANY SNAPSHOT
TABLE 121. GI DYNAMICS: OPERATING SEGMENT
TABLE 122. GI DYNAMICS: PRODUCT PORTFOLIO
TABLE 123. GI DYNAMICS: PRODUCT PORTFOLIO
TABLE 124. GI WINDOWS: COMPANY SNAPSHOT
TABLE 125. GI WINDOWS: OPERATING SEGMENT
TABLE 126. GI WINDOWS: PRODUCT PORTFOLIO
TABLE 127. GI WINDOWS: PRODUCT PORTFOLIO
TABLE 128. MEDTRONIC: COMPANY SNAPSHOT
TABLE 129. MEDTRONIC: OPERATING BUSINESS SEGMENTS
TABLE 130. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 131. OBALON THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE 132. OBALON THERAPEUTICS: OPERATING SEGMENT
TABLE 133. OBALON THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 134. RESHAPE LIFESCIENCES: COMPANY SNAPSHOT
TABLE 135. RESHAPE LIFESCIENCES INC.: PRODUCT PORTFOLIO
TABLE 136. RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 137. SPATZ FGIA: COMPANY SNAPSHOT
TABLE 138. SPATZ FGIA: OPERATING SEGMENT
TABLE 139. SPATZ FGIA: PRODUCT PORTFOLIO
TABLE 140. USGI MEDICAL: COMPANY SNAPSHOT
TABLE 141. USGI MEDICAL: OPERATING SEGMENTS
TABLE 142. USGI MEDICAL: PRODUCT PORTFOLIO
TABLE 143. RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO

FIGURE 01. GLOBAL ENDOSCOPY DEVICES MARKET: SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021*
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021*
FIGURE 01. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02. MODERATE BARGAINING POWER OF BUYERS
FIGURE 03. MODERATE THREAT OF SUBSTITUTES
FIGURE 04. MODERATE THREAT OF NEW ENTRANTS
FIGURE 05. HIGH INTENSITY OF RIVALRY
FIGURE 06. TOP PLAYER POSITIONING, 2019
FIGURE 07. DRIVERS, RESTRAINTS, OPPORTUNITIES
FIGURE 08. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 09. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEMS, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES MARKET FOR ASPIRATION THERAPY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTIONS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR LAP BAND SURGERY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 19. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY COUNTRY, 2019 & 2028
FIGURE 20. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY COUNTRY, 2019 & 2028
FIGURE 21. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY COUNTRY, 2019 & 2028
FIGURE 22. REGION WISE PREVALENCE OF DIABETES, 2019, 2030 & 2045
FIGURE 23. SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 24. SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 25. SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 26. SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 27. APOLLO ENDOSURGERY: NET SALES, 2018–2020 ($MILLION)
FIGURE 28. APOLLO ENDOSURGERY: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 29. APOLLO ENDOSURGERY: REVENU.S.ARE BY REGION, 2020 (%)
FIGURE 30. MEDTRONIC: NET SALES, 2018–2020 ($MILLION
FIGURE 31. MEDTRONIC: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 32. MEDTRONIC: REVENU.S.ARE BY REGION, 2020 (%)
FIGURE 33. OBALON THERAPEUTICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 34. RESHAPE LIFESCIENCES INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. RESHAPE LIFESCIENCES: REVENU.S.ARE BY REGION, 2020 (%)